Deals
Takeda CEO Seeks Deals to Form Identity Beyond Japan Drug Market
- Challenge is to find right asset at ‘price that makes sense’
- Japan’s top drugmaker also looks for branches to cut, CEO says
This article is for subscribers only.
Japan’s biggest drugmaker is ready to take on more partnerships and deals -- at the right price -- as it seeks to build an identity beyond the pharmacy shelves of its home market.
While Takeda Pharmaceutical Co. still has the scope for acquisitions after the $4.66 billion purchase of U.S. biotech Ariad Pharmaceuticals Inc. in January, selling some assets, limiting its debt levels and preserving its credit ratings are also goals, Chief Executive Officer Christophe Weber said Thursday in an interview in London. The company already has about 180 research partnerships, and will form more of them to build its pipeline.